Search General Info
Search Education
Search Partnering Companies
Neuro-Innovators, LLC
3:00 PM - 3:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Neuro-Innovators, LLC (NIV) is a clinical stage drug company. Its purpose, accelerate brain neuroplasticity (capacity of the brain to remodel, rewire, recover) in patients with brain injury & disease.
NIV engineers novel combinations of existing drugs known to enhance neuroplasticity and impact multiple mechanisms of action in the brain, specific to a disease/ injury. Using FDA approved drugs, NIV is using the FDA’s 505(b)(2) pathway and Fast Track processes, resulting in shorter time to market (3-5 vs. 10+ yrs) & lower cost (~$32M vs. $1+B for New Chemical Entity).
Our first drug, NIV-001, targets patients with chronic motor deficits due to a stroke. Importantly, motor deficits changes are objectively measurable, lowering FDA approval costs and risk. There are 7M US stroke patients costing $50B annually, and creating significant family, and community burdens.
NIV is raising seed funding: $2M; series A & B: $30M; and an acquisition target in 3 yrs, and commercialize NIV-001 in 5 yr
NIV engineers novel combinations of existing drugs known to enhance neuroplasticity and impact multiple mechanisms of action in the brain, specific to a disease/ injury. Using FDA approved drugs, NIV is using the FDA’s 505(b)(2) pathway and Fast Track processes, resulting in shorter time to market (3-5 vs. 10+ yrs) & lower cost (~$32M vs. $1+B for New Chemical Entity).
Our first drug, NIV-001, targets patients with chronic motor deficits due to a stroke. Importantly, motor deficits changes are objectively measurable, lowering FDA approval costs and risk. There are 7M US stroke patients costing $50B annually, and creating significant family, and community burdens.
NIV is raising seed funding: $2M; series A & B: $30M; and an acquisition target in 3 yrs, and commercialize NIV-001 in 5 yr
![](https://778c1607566f28c5e8fd-e6db6de54823ad7fd298e0f6ff75b72a.ssl.cf1.rackcdn.com/BIO_4121_EOISBJNL_588_Neuro-Innovators.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
NIV-001
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![Placeholder Photo](/act-root/bio/assets/images/speaker-default.png)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved